youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
ELAN:NYSE
Elanco Animal Health Inc
$24.10
arrow_upward
+4.51%(+1.04) 1D
$24.23
arrow_upward
+0.54% (+0.13)todayPre-market
Closed: Nov 2, 4:00:04 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ELAN...
Open
$23.55
High
$24.22
Low
$23.31
Mkt. cap
12.04B
Avg. vol.
5.03M
Volume
282.00
52-wk high
$27.98
52-wk low
$19.40
EPS
-$0.42
Beta
1.71
Shares outstanding
499.62M
No. of employees
10K
Open
$23.55
High
$24.22
Low
$23.31
Mkt. cap
12.04B
Avg. vol.
5.03M
Volume
282.00
52-wk high
$27.98
52-wk low
$19.40
EPS
-$0.42
Beta
1.71
Shares outstanding
499.62M
No. of employees
10K
News stories
From web sources and news partners
Zacks
·
20 hours ago
RadNet (RDNT) Reports Next Week: Wall Street Expects Earnings Growth
Profile
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world. Wikipedia
About Elanco Animal Health Inc
CEOJeffrey N. Simmons
Employees9.65K
Founded1954
HeadquartersIndianapolis, Indiana, United States
SectorPharmaceutical industry
Websiteelanco.com
Analyst ratings
Based on 14 analysts giving stock ratings to ELAN in the past 3 months
Strong buy
Buy
12
Hold
2
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for ELAN in the last 3 months.
Highest
Current $24.10
$34.00 (+41.08%)
Average
$30.92 (+28.30%)
Lowest
$24.00 (-0.41%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Erin Wright Morgan Stanley | Hold | Maintained | $25.00 | +3.7% | 10/30/2026 |
Andrea Alfonso UBS | Buy | Maintained | $33.00 | +36.9% | 10/26/2026 |
Keith Devas Jefferies | Hold | Downgraded | $24.00 | -0.4% | 10/20/2026 |
Chris Schott J.P. Morgan | Buy | Maintained | $33.00 | +36.9% | 10/16/2026 |
Matthew Dellatorre Goldman Sachs | Buy | Initiated | $32.00 | +32.8% | 10/15/2026 |
Daniel Clark Leerink Partners | Buy | Reiterated | $34.00 | +41.1% | 10/01/2026 |
Jonathan Block Stifel Nicolaus | Buy | Reiterated | - | - | 09/18/2026 |
Steve Scala TD Cowen | Buy | Reiterated | $32.00 | +32.8% | 08/25/2026 |
Glen Santangelo Barclays | Buy | Maintained | $30.00 | +24.5% | 08/21/2026 |
Michael Ryskin Bank of America Securities | Buy | Maintained | $34.00 | +41.1% | 08/12/2026 |
Brandon Vazquez William Blair | Buy | Maintained | - | - | 08/12/2026 |
David Westenberg Piper Sandler | Buy | Maintained | $30.00 | +24.5% | 08/10/2026 |
Daniel Grosslight Citi | Buy | Maintained | $34.00 | +41.1% | 08/06/2026 |
Scott Schoenhaus KeyBanc | Buy | Maintained | $30.00 | +24.5% | 08/06/2026 |
Jasper Hellweg Argus Research | Buy | Maintained | - | - | 06/23/2026 |
Umer Raffat Evercore ISI | Buy | Maintained | - | - | 05/11/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $30.00 | +24.5% | 02/25/2026 |
Next call in 3 days
Fri, Nov 6, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.20
Revenue / Est. (USD)
- / 1.21B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.14B | 1.14B | 1.37B | 1.37B |
Cost of goods sold | 530.00M | 555.00M | 586.00M | 570.00M |
Cost of revenue | 530.00M | 555.00M | 586.00M | 570.00M |
Research and development expenses | 89.00M | 93.00M | 97.00M | 92.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 351.00M | 331.00M | 381.00M | 449.00M |
Operating expense | 580.00M | 563.00M | 616.00M | 680.00M |
Total operating expenses | 1.11B | 1.12B | 1.20B | 1.25B |
Operating income | 27.00M | 26.00M | 169.00M | 118.00M |
Other non operating income | 2.00M | -15.00M | -8.00M | -11.00M |
EBT including unusual items | -50.00M | -259.00M | 87.00M | 56.00M |
EBT excluding unusual items | -25.00M | -37.00M | 103.00M | 65.00M |
Income tax expense | -16.00M | 17.00M | 30.00M | 2.00M |
Effective tax rate | 32.00% | -6.56% | 34.48% | 3.57% |
Other operating expenses | - | - | - | - |
Net income | -34.00M | -276.00M | 57.00M | 54.00M |
Net profit margin | -2.99% | -24.13% | 4.16% | 3.95% |
Earnings per share | 0.19 | 0.13 | 0.40 | 0.34 |
Interest and investment income | - | 45.00M | - | - |
Interest expense | -52.00M | -105.00M | -57.00M | -59.00M |
Net interest expenses | -52.00M | -60.00M | -57.00M | -59.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 195.00M | 194.00M | 335.00M | 283.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events